China Digest: Biopharma startup Alebund raises $60m; Revere VC closes seed round
May 11, 2021
Chinese biopharmaceutical startup Alebund Pharmaceuticals has secured $60 million in a Series B round, while San Francisco and Hong Kong-based asset management firm Revere VC has closed its seed round.
Alebund Pharma nets $60m in Series B round
Alebund Pharmaceuticals, a biopharmaceutical startup that develops innovative therapies for the treatment of renal diseases, has bagged $60 million in a Series B round of financing, the startup announced on May 9.
The Series B round was led by Quan Capital, a life sciences venture capital (VC) firm, with participation from an unspecified sovereign wealth fund; 3E Bioventures Capital, an investor of life sciences and biomedical technologies; and healthcare investment platform Sherpa Healthcare Partners.